Find the top 20 product net sales from continuing operations in 2024. Annual Sales of Tasigna reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 … Tasigna's patent US 7,169,791 expired March 17, 2023, triggering generic competition [1]. The reimbursement environment also evolved, as Tasigna is reimbursed under Medicare Part D with average sales price-based payments post-patent expiry [2]. The Tasigna market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tasigna market comprehensively. Novartis ' blockbuster drug Tasigna (nilotinib) is set to lose its exclusive status in the US in January 2024. A pivotal treatment for chronic myeloid leukemia (CML), with forecasted 2023 sales of $1.8 billion, Tasigna faces a significant sales decline. North America is the largest market for Tasigna Market, accounting for approximately 45% of global sales. The region's growth is driven by increasing cancer prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative therapies. The global Tasigna market size was US$ 1590 million in 2024 and is forecast to a readjusted size of US$ 1088 million by 2031 with a CAGR of -5.4% during the forecast period 2025-2031. The Tasigna market's growth trajectory over the next seven years is characterized by a complex interplay of demand-side and supply-side dynamics. On the demand side, the rising global prevalence of CML, driven by demographic aging and improved diagnostic detection, will sustain a steady increase in eligible patient populations. The value covers manufacturer net sales of the originator Tasigna capsules, Azurity's Danziten nilotinib tartrate tablets and every generic nilotinib capsule sold for approved chronic myeloid leukemia indications in adults and children. Home – Pharma & Healthcare – Tasigna Market Analysis Tasigna Market Analysis 2026 The global Tasigna market size was USD 9715.5 million in 2024. Increased awareness and diagnosis of CML lead to higher treatment rates is expected to boost sales to USD 24610.92 million by 2031, with a Compound Annual Growth Rate (CAGR) of 14.20% from 2024 to 2031. LPI is a top market research company certified by the industry. Its team of market analysts provides clients with high-quality customized market research and industry research reports. The US is one of the most important markets for Tasigna, as it contributed 39% of the drug's total historical revenue from 2008 to 2022. Global Info Research owns large basic databases and expert resourcesGlobal Info Research owns large basic databases and expert resources, focusing on Industry Analysis, management consulting, IPO consulting, database top industries services as well. Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. Compare prices and print coupons for Tasigna and other drugs at CVS, Walgreens, and other pharmacies. Prices start at $2,161.50 Tasigna: A Comprehensive Insight into the Global Market Tasigna, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, has gained significant market traction in recent years. This report provides an in-depth analysis of the global Tasigna market, including market trends, industry developments, key drivers, and future growth prospects. Further, the study has identified and studied all the major players operating in the global tasigna drug market space and equated based on various parameters such as market revenue, annual sales volume, historical growth rate, and business strategies. Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. Compare Tasigna 150 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for tasigna. Discounts up to 80% off the retail price. Compare Tasigna prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. In a conference in September, Bloomberg says Herve Hoppenot, who oversees cancer drugs at Novartis, said the company wants Tasigna to "cannibalize" Gleevec until Gleevec is hit by generics. Chapter 3: Detailed analysis of Tasigna manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers … The report offers Tasigna Market Dynamics, Comprises Industry development drivers, challenges, opportunities, threats and limitations. A report also incorporates Cost Trend of products, Mergers & Acquisitions, Expansion, Crucial Suppliers of products, Concentration Rate of Steel Coupling Economy. Global Tasigna Market Research Report covers Market Effect Factors investigation chiefly included … These drugs are enormously profitable for Novartis. Gleevec is Novartis' best-selling drug; sales were $4.7 billion in 2012. Tasigna had sales of $1 billion. Sales from that second-generation TKI reached $1.55 billion, up 7% year over year. Thanks to a label update in 2017, some leukemia patients may stop treatment with Tasigna after sustained response. 6Wresearch actively monitors the United States (US) Tasigna Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 … With Tasigna sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tasigna industry. This Insight Report provides a comprehensive analysis of the global Tasigna landscape and highlights key trends related to product segmentation, company formation, revenue, and market … Tasigna is a medicine for treating chronic myelogenous leukaemia (CML) – a blood cancer – in patients who have been newly diagnosed or who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them. Tasigna is only for patients with a special chromosome in their cancer cells called the Philadelphia chromosome. Tasigna is used during the … Novartis Patient Support™ Novartis Patient Support is a program designed to help your eligible patients start, stay, and save on TASIGNA. To learn more, call 1-800-282-7630. The Tasigna market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tasigna market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. Tasigna Market analysis indicates the market was valued at USD 1.31 Billion in 2025 and is anticipated to reach USD 3.13 Billion by 2035 with a CAGR of 9.1% over the forecast timeline. 6Wresearch actively monitors the North America Tasigna Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Our insights help businesses to make data-backed strategic decisions with ongoing market dynamics. Our analysts track relevent industries related to the North America Tasigna Market, allowing our … In the US (USD 12.0 billion, +23%), sales growth was mainly driven by Kisqali, Entresto, Kesimpta, Cosentyx and Scemblix, partly offset by the impact of generic competition on Tasigna and Sandostatin Group. In 2024, Tasigna generated $848 million in U.S. sales, while global revenue declined 8% to $1.7 billion, a drop attributed to "lower demand and increasing competition" across all regions. What patents protect Tasigna and how strong is the patent estate for nilotinib? Featured snippet answer: Tasigna's protection is sustained by a layered estate covering composition of matter, formulations, and additional patentable subject matter such as methods of use and treatment regimens. Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib's side-effect profile over Bristol's Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says. Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia. Includes Tasigna side effects, interactions and indications.